Literature DB >> 11064493

HIV and HCV infection among injecting drug users.

H Hagan1, D C Des Jarlais.   

Abstract

BACKGROUND: Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) are the two blood-borne pathogens most commonly transmitted among injection drug users via multi-person use of syringes and other injection equipment. However, important differences exist in the epidemiology of HIV and HCV within different populations of intravenous drug users.
METHOD: A literature review was carried out to summarize publications describing the epidemiology and natural history of HIV and HCV in injection drug users.
RESULTS: Among injection drug users worldwide, HIV prevalence varies from <5% to >80%, with annual HIV incidence between <1% and 50%. More consistency is shown in HCV prevalence (50-90%) and incidence (10-30% per year). Host, environmental and viral factors that favor rapid spread of HCV among IDUs suggest that HCV infection in a population of injection drug users may become endemic over a relatively short period of time. Lower transmission efficiency for HIV also indicates that its spread among injection drug users may be somewhat slower.
CONCLUSIONS: Successful efforts to prevent transmission of blood-borne viruses among IDUs typically result in risk reduction; however, no intervention has resulted in elimination of risk behavior. To reduce HIV transmission, risk reduction may be sufficient, whereas control of HCV may necessitate the use of injection practices that guarantee elimination of exposure to equipment contaminated with even small amounts of blood.

Entities:  

Mesh:

Year:  2000        PMID: 11064493

Source DB:  PubMed          Journal:  Mt Sinai J Med        ISSN: 0027-2507


  41 in total

Review 1.  Updating the infection risk reduction hierarchy: preventing transition into injection.

Authors:  David Vlahov; Crystal M Fuller; Danielle C Ompad; Sandro Galea; Don C Des Jarlais
Journal:  J Urban Health       Date:  2004-03       Impact factor: 3.671

2.  Harmful microinjecting practices among a cohort of injection drug users in vancouver Canada.

Authors:  Beth Rachlis; Elisa Lloyd-Smith; Will Small; Diane Tobin; Dave Stone; Kathy Li; Evan Wood; Thomas Kerr
Journal:  Subst Use Misuse       Date:  2010-07       Impact factor: 2.164

3.  Design and feasibility of a randomized behavioral intervention to reduce distributive injection risk and improve health-care access among hepatitis C virus positive injection drug users: the Study to Reduce Intravenous Exposures (STRIVE).

Authors:  Farzana Kapadia; Mary H Latka; Holly Hagan; Elizabeth T Golub; Jennifer V Campbell; Micaela H Coady; Richard S Garfein; David L Thomas; Sebastian Bonner; Thelma Thiel; Steffanie A Strathdee
Journal:  J Urban Health       Date:  2007-01       Impact factor: 3.671

4.  Income level and drug related harm among people who use injection drugs in a Canadian setting.

Authors:  Cathy Long; Kora DeBeck; Cindy Feng; Julio Montaner; Evan Wood; Thomas Kerr
Journal:  Int J Drug Policy       Date:  2013-12-01

5.  A time since onset of injection model for hepatitis C spread amongst injecting drug users.

Authors:  S Corson; D Greenhalgh; S J Hutchinson
Journal:  J Math Biol       Date:  2012-08-28       Impact factor: 2.259

6.  Potential impact of vaccination on the hepatitis C virus epidemic in injection drug users.

Authors:  Judith A Hahn; Dennis Wylie; Jesse Dill; Maria S Sanchez; James O Lloyd-Smith; Kimberly Page-Shafer; Wayne M Getz
Journal:  Epidemics       Date:  2009-03       Impact factor: 4.396

7.  The Everyday Violence of Hepatitis C Among Young Women Who Inject Drugs in San Francisco.

Authors:  Philippe Bourgois; Bridget Prince; Andrew Moss
Journal:  Hum Organ       Date:  2004-09

8.  Injection drug users and the provision of hepatitis C-related services in a nationwide sample of drug treatment programs.

Authors:  Zdravko P Vassilev; Shiela M Strauss; Janetta Astone; Don C Des Jarlais
Journal:  J Behav Health Serv Res       Date:  2004 Apr-Jun       Impact factor: 1.505

9.  Parenteral transmission of the novel human parvovirus PARV4.

Authors:  Peter Simmonds; Ashleigh Manning; Rachel Kenneil; Frances W Carnie; Jeanne E Bell
Journal:  Emerg Infect Dis       Date:  2007-09       Impact factor: 6.883

10.  HIV/hepatitis prevention in drug abuse treatment programs: guidance from research.

Authors:  James L Sorensen; Carmen L Masson; David C Perlman
Journal:  Sci Pract Perspect       Date:  2002-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.